Additionally, targeting both EGFR and IGF1R in ACC through combined TKI therapy (Erlotinib and IGF1R inhibitor NVP-AEW541) has been explored preclinically, showing enhanced tumor inhibition compared to single-agent approaches, highlighting the potential for synergistic effects in dual-targeted strategies (52). Here, IGF1R is linked to neoplasm.